To own ADMA Biologics, you need to believe that its plasma derived portfolio can keep generating healthy earnings from largely fixed manufacturing assets, even as the standard immunoglobulin market gets more crowded. The reiterated 2026 revenue guide of at least US$530 million suggests that management sees enough demand visibility to support that view.
The near term catalyst still depends on execution in driving higher margin ASCENIV volumes and maintaining gross margins that the analyst consensus Narrative on Simply Wall St links to the FDA approved yield enhancement process. The biggest risk remains product concentration and competitive pressure on therapies like BIVIGAM, which could strain pricing and compress profitability if conditions worsen.
The most relevant update for that thesis is the third quarter 2026 report, which showed US$141.1 million in sales and US$49.88 million in net income, with basic and diluted EPS from continuing operations at US$0.22. Those figures, alongside nine month revenue of US$379.99 million and net income of US$133.03 million, provide a current snapshot of how the model is performing.
In light of the earlier cuts to guidance referenced in the analyst consensus Narrative on Simply Wall St, this latest quarter frames the near term debate around consistency. Investors now weigh ongoing ASCENIV adoption, gross margin support from the yield enhancement process and progress on SG 001 against concentrated products, lawsuits tied to ASCENIV distribution and any renewed pressure on immunoglobulin pricing or ordering patterns.
ADMA Biologics' narrative projects US$769.2 million in revenue and US$293.5 million in earnings by 2029, based on analysts' models. This implies 14.0% yearly revenue growth and an earnings increase of about US$111.1 million from the current US$182.4 million level.
Uncover why ADMA Biologics' fair value indicates a 30% potential upside to its current price, which could narrow quickly.
One alternate view on ADMA Biologics leans heavily on the share repurchase program as the real catalyst. The most optimistic analysts were penciling in US$893.6 million of 2029 revenue and US$345.1 million of earnings before this latest quarter and guidance update. Your own read may shift if buybacks and earnings now look different in combination.
Explore 6 other ADMA Biologics fair value estimates, including one that suggests potential upside of as much as 193% from the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Once you have a view on ADMA Biologics, it can help to widen the lens and see how other businesses line up on quality, balance sheet strength, income potential and perceived mispricing. The Simply Wall St Screener lets you filter for these traits quickly so you can spend more time weighing the story behind each ticker.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com